CymaBay Therapeutics, Inc. (CBAY) |
|
9.59 0.45 (4.92%)
|
03-17 16:00 |
|
Open: |
9.05 |
Pre. Close: |
9.14 |
|
High:
|
10.05 |
Low:
|
9.05 |
|
Volume:
|
4,187,036 |
Market Cap:
|
908(M) |
|
|
|
Technical analysis |
as of: 2023-03-20 8:44:46 AM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 11.73  One year: 13.71 |
| Support: |
Support1: 8.38 Support2: 7.34 |
| Resistance: |
Resistance1: 10.05 Resistance2: 11.73 |
| Pivot: |
8.72 |
| Moving Average: |
MA(5): 9.22 MA(20): 8.56
MA(100): 5.96 MA(250): 4.2 |
| MACD: |
MACD(12,26): 0.4 Signal(9): 0.3 |
| Stochastic oscillator: |
%K(14,3): 80.3  %D(3): 81.7 |
| RSI: |
RSI(14): 66.2 |
| 52-week: |
High: 10.05 Low: 1.66 |
| Average Vol(K): |
3-Month: 1,629 (K) 10-Days: 2,010 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ CBAY ] has closed below upper band by 7.8%. Bollinger Bands are 49.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
10.06 - 10.1 |
10.1 - 10.13 |
|
Low:
|
8.96 - 9 |
9 - 9.04 |
|
Close:
|
9.52 - 9.59 |
9.59 - 9.65 |
|
Company Description |
|
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California. |
Headline News |
Mon, 20 Mar 2023
Analysts Offer Predictions for CymaBay Therapeutics, Inc.'s Q1 2023 ... - MarketBeat
Sat, 18 Mar 2023
HC Wainwright Boosts CymaBay Therapeutics (NASDAQ:CBAY ... - MarketBeat
Thu, 16 Mar 2023
CymaBay Reports Fourth Quarter and Year Ended December 31, 2022 Financial Results and Provides Corporate Update - Yahoo Finance
Thu, 16 Mar 2023
After-Hours Earnings Report for March 16, 2023 : FDX, MNTK ... - Nasdaq
Tue, 14 Mar 2023
Cymabay Therapeutics Inc : A loss of 30 cents per share ... - Kalkine Media
Tue, 14 Mar 2023
Cubist Systematic Strategies LLC increases its stake in CymaBay ... - Best Stocks
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
95 (M) |
| Shares Float |
0 (M) |
|
% Held by Insiders
|
0.3 (%) |
|
% Held by Institutions
|
76.5 (%) |
|
Shares Short
|
4,940 (K) |
|
Shares Short P.Month
|
4,430 (K) |
Stock Financials |
|
EPS
|
-1.35 |
|
EPS Est Next Qtl
|
-0.16 |
|
EPS Est This Year
|
-0.82 |
|
EPS Est Next Year
|
-0.75 |
|
Book Value (p.s.)
|
0.7 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
0 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
0 (M) |
Stock Valuations |
|
PE Ratio
|
-7.16 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
13.5 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
